Programme Overview

ILCA 2019 / Programme Overview
Pre-Conference
General Session
Symposium
State-of-the-Art Lecture
Industry Symposium
Workshops

13:00 – 18:15

ILCA Pre-Conference Workshop on Metabolism and Liver Cancer: From Mechanism to Treatment

Chairs: Valerie Paradis, MD, PhD (France), Jean-François Dufour, MD, PhD (Switzerland) and Amit Singal, MD (USA)

18:30 – 19:30

Young Investigator Session

Chair: Maria Reig, MD, PhD (Spain) and Jean-Charles Nault, MD (France)

  • How to Publish in Journal of Hepatology?
    Bruno Sangro, MD, PhD (Spain)

08:00 – 09:30

ILCA Symposium 1: The Cell of Origin of Liver Cancer

Chair: Augusto Villanueva, MD, PhD (USA)

  • Hepatocytes, Cholangiocytes, Stem Cells, etc. Who to Blame for Liver Cancer Development?
    Lars Zender, MD, PhD (Germany)
  • Why Inflammation and Regeneration are Key to Liver Cancer Development?
    Nabil Djouder, PhD (Spain)
  • Cell of Origin in Human Samples: Lessons from Genomic Studies
    Anuradha Budhu, PhD (USA)

09:30 – 10:15

State-of-the-Art Lecture 1: The Patient Perspective on Cancer Treatment

Chair: Morris Sherman, MD, PhD (Canada)
Speaker: Melinda Bachini (USA)

10:15 – 10:45

Coffee and Networking Break

10:45 – 11:00

Welcome Address

Morris Sherman, MD, PhD (Canada), Jessica Zucman-Rossi, MD, PhD (France), Sandrine Faivre, MD, PhD (France) and Bruno Sangro, MD, PhD (Spain)

11:00 – 12:30

General Session 1: Molecular Pathogenesis

12:30 – 12:45

Session Break

12:45 – 14:15

Industry Partner Lunch Symposium

14:15 – 14:30

Session Break

14:30 – 16:00

General Session 2: Clinical Trials

16:00 – 16:45

Coffee and Networking Break

16:00 – 16:45

ILCA General Assembly (members only)

16:45 – 18:15

ILCA Symposium 2: Peri Hilar Cholangiocarcinoma

Chairs: Eric Vibert, MD, PhD (France) and Christian Toso, MD, PhD (Switzerland)

  • Patient Selection and Optimization for Surgery
    Masato Nagino, MD (Japan)
  • Resection or Transplantation for Cholangiocarcinoma
    Julie Heimbach, MD (USA)
  • Histological and Morphological Heterogeneity of Biliary Stenosis
    Tom H. Karlsen, MD, PhD (Norway)

18:15 – 19:15

Welcome Reception

07:30 – 08:30

Industry Partner Symposium

08:30 – 9:45

ILCA − EASL Symposium

  • ILCA lecture
  • EASL Lecture
  • Consensus Lecture

09:45 – 10:45

Networking Break and e-Poster Viewing Tour

10:45 – 12:00

Presidential Session

Chairs: Morris Sherman, MD, PhD (Canada), Jessica Zucman-Rossi, MD, PhD (France), Sandrine Faivre, MD, PhD (France) and Bruno Sangro, MD, PhD (Spain)

12:00 – 12:15

Session Break

12:15 – 13:45

Industry Partner Lunch Symposium

13:45 – 14:00

Session Break

14:00 – 15:15

Ground Rounds Session

Multidisciplinary Case Presentations and Debate
Chair: Laura Kulik, MD (USA)
Expert Panel: Neehar Parikh, MD (USA), Gonzalo Sapisochin, MD, PhD (Canada) and Masatoshi Kudo MD, PhD (Japan)
Speaker: Jasmine Sinha, MD (USA)

15:15 – 15:45

Coffee and Networking Break

15:45 – 17:15

General Session 3: Epidemiology, Diagnosis, Staging

17:15 – 17:30

Session Break

16:30 – 18:30

Workshop for Nurses

Chair: HoChong Gilles (USA)

17:30 – 18:30

ILCA Single Topic Workshops (STW)

STW 1: Molecular Diversity in HCC
Novel Models to Explore Molecular Diversity in HCC
Amaia Lujambio, PhD (USA) and Jean-Charles Nault, MD (France)

STW 2: Systemic Therapy
How to Sequence Treatment
Britsi Basu, MD, PhD (UK) and Andrew Zhu, MD, PhD (USA)

STW 3: Surgery for Primary Liver Cancer
Transplantation for Cholangiocarcinoma
Lewis Roberts, MD, PhD (USA)

STW 4: Radiology
Imaging of HCC Response to Loco-Regional and Systemic Therapy
Riccardo Lencioni, MD (Italy/USA) and Tae Kyoung Kim, MD, PhD (Canada)

18:30 – 19:00

Industry Partner Workshops

08:00 – 09:00

Industry Partner Symposium

09:00 – 10:15

ILCA − AASLD Symposium

Chairs: Jessica Zucman-Rossi, MD, PhD (France) and Josep M. Llovet, MD, PhD (Spain/USA)

  • End-Points and Rationale for Phase III Trials in HCC: Adjuvant, Intermediate and Advanced HCC
    Richard Finn, MD (USA)
  • Immunotherapy for HCC: What’s Next?
    Anthony El-Khoueiry, MD (USA)
  • Pathogenesis and Systemic Management of iCCA: Role of Molecular Therapies
    Gregory Gores, MD (USA)

10:15 – 10:45

State-of-the-Art Lecture 2: Molecular Lessons Learnt from Clinical Trials in the Last Decade

Speaker: Andrew Zhu, MD, PhD (USA)

10:45 – 11:00

Coffee and Networking Break

11:00 – 12:30

General Session 4: Treatment and Response

12:30 – 12:45

Closing Ceremony

Contact Us

Keep Me Updated